Rachel M. Leskowitz, Ph.D.
Affiliations: | 2014 | Cell and Molecular Biology | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Cell Biology, Immunology, Virology BiologyGoogle:
"Rachel Leskowitz"Parents
Sign in to add mentor| Hildegund Ertl | grad student | 2014 | Penn | |
| (EBNA1-specific T cell responses during persistent rhesus LCV infection and the development of a novel therapeutic prototype vaccine for EBV-associated diseases.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bagley SJ, Logun M, Fraietta JA, et al. (2024) Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nature Medicine |
| Garfall AL, Cohen AD, Susanibar-Adaniya SP, et al. (2022) Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discovery |
| Gladney W, Hexner E, Salas-McKee J, et al. (2020) Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products Cytotherapy. 22: S35 |
| Gohil M, Dai A, Mackey S, et al. (2019) Myeloid derived suppressor cells (MDSCS) reduce the manufacturing feasibilty of gene modified T cells. Cytotherapy. 21: S19 |
| Ohayon Y, Corl C, Leskowitz R, et al. (2018) Robust automated cell counter and viability measurement for engineered T cell product release Cytotherapy. 20: S69 |
| Davis M, Fesnak A, Leskowitz R, et al. (2017) Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL) Cytotherapy. 19: S118-S119 |
| Levine B, Leskowitz R, Davis M. (2015) Personalized gene therapy locks out HIV, paving the way to control virus without antiretroviral drugs. Expert Opinion On Biological Therapy. 15: 831-43 |
| Leskowitz R, Fogg MH, Zhou XY, et al. (2014) Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques. Journal of Virology. 88: 4721-35 |
| Silveira EL, Fogg MH, Leskowitz RM, et al. (2013) Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques. Journal of Virology. 87: 13904-10 |
| Leskowitz RM, Zhou XY, Villinger F, et al. (2013) CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques. Journal of Virology. 87: 8351-62 |